프리시젼바이오

335810· KOSDAQ· Health Care· Health Care Equipment & Services

₩1,431-0.28%

2026-11-02

Financials

Valuation Metrics

프리시젼바이오's Market Cap is ₩314B. At end of 2025 it was ₩583B. Ranked #2002 of 2,412 in KR market (top 83%), #1267 of 1,632 on KOSDAQ (top 78%), #84 of 94 in Health Care Equipment & Services (top 89%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	31.41B KRW	KR#2,002/2,412 Sec#84/94
Revenue	23.66B KRW	KR#2,100/2,412 Sec#71/94
Net Income	-6.35B KRW	KR—/2,412 Sec—/94
Total Assets	60.48B KRW	KR#2,096/2,412 Sec#67/94
Net Assets	42.05B KRW	KR#2,016/2,412 Sec#68/94
Employees	96	KR#1,666/2,412 Sec#63/94
Value
P/B	0.75x	KR#1,272/2,412 Sec#28/94
P/S	1.33x	KR#1,626/2,412 Sec#40/94
FCF Yield	-5.32%	KR—/2,412 Sec—/94
Profitability
ROE	-15.10%	KR#2,019/2,412 Sec#73/94
ROA	-10.50%	KR#2,112/2,412 Sec#75/94
Op. Margin	-15.29%	KR#2,066/2,412 Sec#68/94
Revenue Growth	22.18%	KR#511/2,412 Sec#27/94
Financial Health
Debt Ratio	43.82%	KR#866/2,412 Sec#46/94
Total Debt	11.89B KRW	KR#1,562/2,412 Sec#47/94
FCF	-1.67B KRW	KR#1,316/2,412 Sec#40/94
Cash	1.55B KRW	KR#2,286/2,412 Sec#93/94
Current Ratio	1.51x	KR#1,192/2,412 Sec#65/94
Performance
1Y Return	-43.21%	KR#2,019/2,412 Sec#72/94
1M Return	-3.70%	KR#899/2,412 Sec#41/94
From 52W High	-59.17%	KR#1,603/2,412 Sec#56/94
1Y MDD	-62.46%	KR#1,628/2,412 Sec#57/94
Trading
Volume	4,107 shares	KR#2,334/2,412 Sec#94/94
Trading Value	5.9M KRW	KR#2,369/2,412 Sec#94/94
Foreign Own.	0.18%	KR#2,264/2,412 Sec#86/94
Per Share
EPS	-289 KRW	KR—/2,412 Sec—/94
BPS	1,916 KRW	KR#2,095/2,412 Sec#72/94

Company Info

CEO 김한신

Employees 96

Founded 2009

HQ 대전시 유성구, KR

Website precision-bio.com/

동사는 2009년 테라웨이브㈜ 설립으로 첨단 광학분석기기 제작 기술을 발전시키고, 2015년 나노디텍을 자회사로 편입해 글로벌 체외진단 업체로의 도약 기반을 마련함. 인공위성 카메라 이미징 기술을 활용해 심근경색, 감염성 질환 등의 진단제품을 생산하며, 2021년부터 임상화학진단 제품을 본격 생산하여 검사기와 카트리지를 판매함. 디지털 헬스케어 플랫폼 개발을 통해 기존 현장진단 제품과 결합해 시너지를 창출하고 있음. 프리시젼바이오는 2009년에 설립되었으며 대전시 유성구에 본사를 두고 있습니다.